Eli Lilly and Company
LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The compaā¦ read more
Healthcare
Drug ManufacturersāGeneral
53 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$985.08
Price+0.80%
$7.83
1Y
Price
Market Cap
$929.282b
Large
Price/Earnings 3y Avg5y Avg
42.8x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+43.5%
EBITDA Margin+34.4%
Net Profit Margin+3.5%
Free Cash Flow Margin+43.5%
EBITDA Margin+34.4%
Net Profit Margin+3.5%
Free Cash Flow MarginRevenue
$65.179b
+44.7%
1y CAGR+32.1%
3y CAGR+24.3%
5y CAGREarnings
$20.638b
+94.9%
1y CAGR+60.3%
3y CAGR+48.2%
5y CAGREPS
$22.95
+96.0%
1y CAGR+62.1%
3y CAGR+49.6%
5y CAGRBook Value
$26.535b
$112.476b
Assets$85.941b
Liabilities$42.503b
DebtDebt to Assets
37.8%
1.5x
Debt to EBITDAFree Cash Flow
$8.972b
+2065.6%
1y CAGR+670.1%
3y CAGR+498.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company